A groundbreaking study published in *Nature Communications* has found that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may slow biological aging in adults living with HIV. Conducted by researchers at the University of California San Diego, the randomized, double-blind, placebo-controlled trial involved 108 participants with HIV-associated lipohypertrophy. Over a 32-week period, those receiving semaglutide showed a 9% reduction in biological aging markers across various epigenetic clocks, particularly those linked to inflammation and metabolic health. This suggests that the drug may help mitigate age-related diseases by reducing chronic immune activation and excess abdominal fat. First author Michael Corley noted that while the study focused on a specific group, the implications could extend to the general population. The research highlights the need for larger clinical trials to further investigate the long-term effects of GLP-1 drugs on aging and to explore potential synergies with lifestyle interventions. The Stein Institute for Research on Aging plans to develop personalized aging dashboards to track biological aging and inform targeted therapies.